Drug Trial Radar · NCT01626664
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Jun 2012
Primary completion
Aug 2015
Study completion Feb 2018
Sponsor
- Lead sponsor
- Kyowa Kirin, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 25, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).
Conditions
- Adult T-cell Leukemia-Lymphoma
Interventions
KW-0761Biological
1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
PralatrexateDrug
30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
gemcitabine plus oxaliplatinDrug
gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
DHAPDrug
dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
University of Miami / Sylvester Comprehensive Cancer Center
Miami, Florida
Northwestern University
Chicago, Illinois
National Cancer Institute
Bethesda, Maryland
Washington University School of Medicine
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan Kettering
New York, New York
Columbia Presbyterian
New York, New York
Weill Cornell Medical College
New York, New York
Montefiore Medical Center
The Bronx, New York
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hospital Universitario Professor Edgard Santos- UFBA
Salvador, Bahia, Brazil
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Sao Paulo- SP, Brazil
CHU de Fort de France
Fort de France Cedex, France
Hospital Necker
Paris, France
Hospital Nacional Edgardo Rebagliati Martins
Lima, Peru
Instituto Oncologico Miraflores
Lima, Peru
Guy's Hospital
London, United Kingdom
Imperial College
London, United Kingdom
Sandwell General Hospital
West Midlands, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.